ALKEM LABORATORIES LTD.
Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

09th August, 2024

To,

The Corporate Relationship Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. ***Scrip Code: 539523***	**National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. ***Scrip Symbol: ALKEM***

Sub: Outcome of Board Meeting held on 09th August, 2024

Dear Sir(s)/ Madam,

This is with reference to our earlier intimation dated 25th July, 2024, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), regarding holding of Board Meeting on 09th August, 2024 to *inter alia* approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2024. The Board of Directors at its meeting held today, i.e. 09th August, 2024 has, *inter alia*:

1. approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2024.

   A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

2. based on recommendation of Nomination and Remuneration Committee and subject to approval of shareholders, approved the appointment of Mr. Rajeev Kher (DIN: 01192524) as an Additional Director designated as an Independent Director on the Board of Directors of the Company for a term of 5 (five) consecutive years w.e.f. 09th August, 2024 upto 08th August, 2029.

The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01.00 p.m.

Kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited consolidated financial results of Alkem Laboratories Limited for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alkem Laboratories Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2024 ("the Statement"), (in which are included financial information from one branch) being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SRM

7. We did not review the interim financial results of 2 Subsidiaries included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs. 2,499 million, total net profit after tax (before consolidation adjustments) of Rs. 115 million and total comprehensive income (before consolidation adjustments) of Rs. 108 million, for the quarter ended 30 June 2024, as considered in the Statement. These interim financial results have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Sreeja Marar
Partner
Membership No.: 111410
UDIN:24111410BKGQOU1349

Mumbai
09 August 2024

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l, (Previously known as S&B Holding B.V with principle place of buisness based at Netherlands redomiciled to Luxembourg w.e.f 16 Oct 2023)	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Enzene Biosciences Ltd, India	Subsidiary
8	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
9	Cachet Pharmaceuticals Pvt Ltd, India	Subsidiary
10	Indchemie Health Specialities Pvt Ltd , India	Subsidiary
11	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
12	Ascend GmbH, Germany	Wholly Owned Subsidiary
13	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
14	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary

15	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
16	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
17	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
18	Pharmacor Ltd , Kenya	Wholly Owned Subsidiary
19	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
20	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
21	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
22	Alkem Foundation. India	Wholly Owned Subsidiary
23	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
24	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
25	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary of Pharmacor Limited, Australia
26	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
27	Alkem Medtech Private Limited, India (incorporated on 27 March 2024)	Wholly Owned Subsidiary

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201
Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.
Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190
Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended 30 June 2024

(₹ In Million except per share data)

	Particulars	Quarter ended			Year ended
		30.06.2024 Unaudited	31.03.2024 (Refer Note 2)	30.06.2023 Unaudited	31.03.2024 Audited
1	**Income**				
	(a) Revenue from Operations	30,318.2	29,358.2	29,677.2	126,675.8
	(b) Other Income	1,203.1	881.7	658.4	3,108.4
	Total Income	31,521.3	30,239.9	30,335.6	129,784.2
2	**Expenses**				
	(a) Cost of materials consumed	8,371.6	7,987.6	8,325.8	32,945.9
	(b) Purchases of stock-in-trade	3,826.6	3,807.0	3,554.7	16,288.7
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,438.7)	(720.6)	105.2	141.2
	(d) Employee benefits expense	6,022.7	5,058.3	5,676.5	22,010.1
	(e) Finance costs	291.1	268.6	297.7	1,124.1
	(f) Depreciation and amortisation expense	804.8	834.3	724.1	2,993.0
	(g) Other expenses	7,449.6	9,206.1	8,123.1	32,835.0
	Total Expenses	25,327.7	26,441.3	26,807.1	108,338.0
3	**Profit before exceptional items and tax (1) - (2)**	6,193.6	3,798.6	3,528.5	21,446.2
4	**Exceptional items (refer note 3)**	-	(125.2)	-	(1,214.9)
5	**Profit before tax (3) + (4)**	6,193.6	3,673.4	3,528.5	20,231.3
6	**Tax expense / (credit)**				
	(a) Current tax	1,244.3	838.5	657.8	4,222.8
	(b) Deferred tax	(553.1)	(209.9)	(7.4)	(2,106.1)
	Total Tax Expense (a + b)	691.2	628.6	650.4	2,116.7
7	**Profit for the period (5) - (6)**	5,502.4	3,044.8	2,878.1	18,114.6
8	**Other Comprehensive Income (net of tax)**				
	(a) (i) Items that will not be reclassified to profit or loss	(49.8)	2.3	(39.5)	(93.4)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	16.0	(2.1)	13.1	29.8
	(b) (i) Items that will be reclassified to profit or loss	74.9	(76.7)	138.6	264.0
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income/Loss (net of tax)	41.1	(76.5)	112.2	200.4
9	**Total Comprehensive Income for the period (7) + (8)**	5,543.5	2,968.3	2,990.3	18,315.0
10	**Profit attributable to**				
	a) Owners of the Company	5,451.6	2,935.6	2,867.3	17,957.7
	b) Non-Controlling Interest	50.8	109.2	10.8	156.9
11	**Other Comprehensive Income attributable to**				
	a) Owners of the Company	44.1	(76.8)	116.9	206.5
	b) Non-Controlling Interest	(3.0)	0.3	(4.7)	(6.1)
12	**Total Comprehensive Income attributable to**				
	a) Owners of the Company	5,495.7	2,858.8	2,984.2	18,164.2
	b) Non-Controlling Interest	47.8	109.5	6.1	150.8
13	**Paid-up Equity Share Capital** (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1
14	**Other Equity**				102,881.5
15	**Earnings Per Share (not annualised for the quarters)**				
	(a) Basic (₹)	45.60	24.55	23.98	150.19
	(b) Diluted (₹)	45.60	24.55	23.98	150.19

el

Notes to the Consolidated Financial results:

1 The above unaudited consolidated financial results are prepared in accordance wilh the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'.

2 The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee on 08 August 2024 and subsequently approved by the Board of Directors at its meeting held on 09 August 2024. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2024. The figures for the quarter ended 31 March 2024 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to 31 December 2023, which were subjected to limited review.

3 a. Consequent to changes in market dynamics and assessment of recoverable value where indicators of impairment were identified, the group has recognized an impairment loss of:
- ₹ 415.6 Million in respect of its plant located at Indore during the previous quarter and year ended 31 March 2024
- ₹ 576.6 Million in respect to the plant located at St. Louis, USA, a unit under S&B Pharma LLC, a subsidiary of the Company in the previous year ended 31 March 2024.
These amounts are reflected under 'Exceptional Items' in the respective periods.

b. During the year ended 31 March 2024, a Cyber security incident which compromised business email IDs of certain employees at one of the Group's subsidiaries, resulted in a fraudulent transfer of ₹ 513.1 Million of which the Group has recovered an amount of ₹ 290.4 Million in quarter ended 31 March 2024 resulting in a net amount of ₹ 222.7 Million shown as 'Exceptional items' in the Statement of Profit and Loss for the year ended 31 March 2024.

4 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

By Order of the Board
For Alkem Laboratories Limited

B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 09 August 2024

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Alkem Laboratories Limited for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Alkem Laboratories Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2024 ("the Statement"), which includes financial information of one branch.

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

SRM

contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Sreeja Marar
Partner
Membership No.: 111410
UDIN:24111410BKGQOT4044

Mumbai
09 August 2024

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201
Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.
Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190
Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30 June 2024

(₹ in Million except per share data)

	Particulars	Quarter ended			Year ended
		30.06.2024 Unaudited	31.03.2024 (Refer note 2)	30.06.2023 Unaudited	31.03.2024 Audited
1	**Income**				
	(a) Revenue from Operations	**25,001.0**	23,653.7	22,531.7	97,477.2
	(b) Other Income	**1,061.0**	837.9	647.0	3,059.9
	Total Income	**26,062.0**	24,491.6	23,178.7	100,537.1
2	**Expenses**				
	(a) Cost of materials consumed	**7,612.3**	6,527.1	6,893.7	27,499.3
	(b) Purchases of stock-in-trade	**2,073.6**	2,699.6	2,451.7	11,287.0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**(856.6)**	86.7	(632.3)	(713.1)
	(d) Employee benefits expense	**4,259.0**	3,434.1	4,140.6	15,602.8
	(e) Finance costs	**214.4**	206.8	214.2	819.1
	(f) Depreciation and amortisation expense	**643.5**	691.0	581.1	2,443.5
	(g) Other expenses	**5,706.4**	6,831.0	6,340.5	24,149.9
	Total Expenses	**19,652.6**	20,476.3	19,989.5	81,088.5
3	**Profit before exceptional items and tax (1) - (2)**	**6,409.4**	4,015.3	3,189.2	19,448.6
4	**Exceptional items (refer note 3)**	**-**	(125.2)	-	(638.3)
5	**Profit before tax (3) + (4)**	**6,409.4**	3,890.1	3,189.2	18,810.3
6	**Tax expense / (credit)**				
	(a) Current tax	**1,112.6**	774.1	539.3	3,332.8
	(b) Deferred tax	**(535.7)**	(133.7)	(64.5)	(1,994.0)
	Total Tax expense (a + b)	**576.9**	640.4	474.8	1,338.8
7	**Profit for the period after tax (5 - 6)**	**5,832.5**	3,249.7	2,714.4	17,471.5
8	**Other Comprehensive Income (net of tax)**				
	(a) (i) Items that will not be reclassified to profit or loss	**(38.2)**	5.5	(24.1)	(66.8)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	**13.4**	(2.0)	8.4	23.3
	(b) (i) Items that will be reclassified to profit or loss	**-**	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	**-**	-	-	-
	Total Other Comprehensive Income/Loss (net of tax)	**(24.8)**	3.5	(15.7)	(43.5)
9	**Total Comprehensive Income for the period (7) + (8)**	**5,807.7**	3,253.2	2,698.7	17,428.0
10	**Paid-up Equity Share Capital** (Face Value ₹ 2 each fully paid up)	**239.1**	239.1	239.1	239.1
11	**Other Equity**				105,307.0
12	**Earnings Per Share (not annualised for the quarters)**				
	(a) Basic (₹)	**48.78**	27.18	22.70	146.13
	(b) Diluted (₹)	**48.78**	27.18	22.70	146.13

Notes to the Standalone Financial results:

1 The above unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 08 August 2024 and subsequently approved by the Board of Directors at its meeting held on 09 August 2024. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2024. The figures for the quarter ended 31 March 2024 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2023, which were subjected to limited review.

3 a. During the quarter and year ended 31 March 2024, the Company has recognized an impairment loss of ₹ 415.6 Million in respect of its plant located at Indore consequent to changes in market dynamics and assessment of recoverable value which is included in 'Exceptional Items'.

b. During the year ended 31 March 2024, a Cyber security incident which compromised business email IDs of certain employees at one of the Company's subsidiaries, resulted in a fraudulent transfer of ₹ 513.1 Million of which the Company has recovered an amount of ₹ 290.4 Million in quarter ended 31 March 2024 resulting in a net amount of ₹ 222.7 Million shown as 'Exceptional items' in the Statement of Profit and Loss for the year ended 31 March 2024.

4 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

By Order of the Board
For Alkem Laboratories Limited

Place: Mumbai
Date: 09 August 2024

B.N. Singh
Executive Chairman
DIN: 00760310

Press Release

Alkem reports Q1FY25 results

Mumbai, 09 August 2024: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the first quarter that ended June 30, 2024. These results were taken on record by the Board of Directors at its meeting held in Mumbai today.

Key highlights of Q1FY25 financial performance

- Total Revenue from Operations was ₹ 30,318 million, with YoY growth of 2.2%.
  - India sales were ₹ 20,223 million, with YoY growth of 6.4%.
  - International sales were ₹ 9,677 million, with YoY de-growth of 4.6%.
- Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were ₹ 6,086 million, resulting in an EBITDA margin of 20.1% vs. 13.1% in Q1FY24. EBITDA increased by 56.4% YoY.
- R&D expenses for the quarter were ₹ 1,257 million, or 4.1% of total revenue from operations, compared to ₹ 1,202 million in Q1FY24 at 4.1% of total revenue from operations.
- Profit before tax (PBT) before exceptional items was ₹ 6,194 million, a growth of 75.5% compared to ₹ 3,529 million in Q1FY24.
- Net Profit (after Minority Interest) was ₹ 5,452 million, with YoY growth of 90.1%.
- According to IQVIA (SSA—Stockist Sales Audit) data, for Q1FY25, the company registered a growth of 8.4% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 8.7%.

Commenting on the Q1FY25 results, Dr Vikas Gupta, CEO of Alkem, said, "We are happy that our efforts to improve profitability have started paying off, and we have seen a marked increase in margins during the quarter. We are committed to maximising our EBITDA margin by carefully managing our product mix, controlling costs, and taking advantage of the favourable raw material pricing environment. The domestic business is our stronghold, and we expect to build on it by furthering the growth of our large brands and bridging portfolio gaps. Simultaneously, we are also focusing on growing our business in emerging markets. During the quarter, an important development was the successful resolution of US FDA's Form 483 at the Baddi facility. At Alkem, we remain steadfast to prioritising quality and regulatory compliance."

Operational Highlights

Domestic Business - In Q1FY25, the Company's India sales increased by 6.4% YoY, recording sales of ₹ 20,223 million compared to ₹ 19,007 million in Q1FY24.

- According to IQVIA (SSA) data, for Q1FY25, the Company delivered a YoY growth of 8.4% compared to the Indian Pharmaceutical Market (IPM) growth of 8.7% YoY.
- We outperformed the IPM in antidiabetic, Neuro/CNS, gastro-intestinal, dermatology, and VMN therapies, and our ranking has improved in Neuro/CNS and Respiratory therapies.
- During the quarter, we launched three new products in the domestic market.
- Uprise D3 is now featured in the Top 100 brands of IPM. In less than four years, Uprise D3 moved from the Top 300 to the top 100 Brands of IPM.

Key performance highlights of therapeutic segments in Q1FY25

Key Therapy segment	Q1FY25			
	Alkem Rank	**YoY change in Rank***	**YoY growth (Alkem)**	**YoY growth (IPM)**
ANTI-DIABETIC	15	Unchanged	9.5%	8.3%
ANTI-INFECTIVES	1	Unchanged	3.3%	6.8%
CARDIAC	26	Unchanged	3.3%	13.3%
DERMA	20	Unchanged	13.8%	9.8%
GASTROINTESTINAL	3	Unchanged	14.3%	11.3%
NEURO / CNS	7	Improved by 1	14.7%	8.8%
PAIN / ANALGESICS	3	Unchanged	5.9%	8.2%
RESPIRATORY	15	Improved by 1	-0.4%	1.9%
VITAMINS/MINERALS/NUTRIENTS	2	Unchanged	12.6%	8.1%
TOTAL	**5**	**Unchanged**	**8.4%**	**8.7%**

**Positive change in rank reflects improvement over the same period in the previous year*
Source: IQVIA SSA Data

International Business - In Q1FY25, the Company's International sales declined by 4.6% YoY, recording sales of ₹ 9,677 million compared to ₹ 10,146 million in Q1FY24.

- US sales for Q1FY25 stood at ₹ 6,416 million, witnessing a decline of 7.7% YoY and a growth of 2.8% on a QoQ basis.
- Other International Markets sales for the quarter were ₹ 3,261 million, recording a YoY growth of 2.2% and 14.2% on a QoQ basis.

Update on USFDA product approvals

- During the quarter, the company launched 1 product in the US and received approval for 3 ANDAs from the USFDA, including one tentative approval.
- As of June 30, 2024, the Company had filed 176 ANDAs and 2 NDAs with the USFDA. Of these, it had received approvals for 148 ANDAs (including 14 tentative approvals) and 2 NDAs.

Update on USFDA Inspections

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Aug-19	EIR Received in Oct 2019
Taloja R&D (India)	Bioequivalence Centre	Oct-22	No observation
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Aug-18	EIR Received in Oct 2018
Note: USFDA conducted a virtual inspection at our manufacturing facilities in Daman from October 5th to 7th, 2020.			

 # EIR – Establishment Inspection Report indicating successful closure of inspection.

Q1FY25 Conference Call at 5 pm IST, August 09, 2024

Alkem will organise a conference call for investors and analysts on Friday, August 09, 2024, from 5:00 pm to 6:00 pm IST to discuss its Q1FY25 financial results.

Alkem Laboratories Ltd. will be represented on the call by:
Dr. Vikas Gupta – CEO
Mr Nitin Agrawal – CFO
Motilal Oswal Securities Ltd. will host the call.

Details of the conference call are as follows:
Time: 5:00 pm IST (GMT + 5:30) on Friday, August 09, 2024

Dial in Details:
India: +91 22 6280 1149 / +91 22 7115 8050
International Toll-Free

USA	: 1 866 746 2133
UK	: 0 808 101 1573
Singapore	: 800 101 2045
Hong Kong	: 800 964 448

Express Join with Diamond Pass
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=2953260&linkSecurityString=1310ba8d94

You are requested to dial in 10 minutes ahead of the scheduled start time.

About Alkem:
Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high-quality medicines to patients. It is the fifth largest pharmaceutical company in the Indian market, with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 19 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centers00 across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit www.alkemlabs.com and follow us on LinkedIn, X, Facebook, and Instagram.

Contact

Investors:
Purvi Shah – Head of Investor Relations
+91 84337 00890
purvi.shah@alkem.com
+91-22-3982 9999 Ext: 9447

Alkem Laboratories Ltd.

Investor Presentation Q1FY25

August 09, 2024

Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and our key global markets.

Should one or more of such risks and uncertainties materialise, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events unless the Law requires it.

Key Highlights of Q1FY25

- Total Revenue from Operations was ₹ 30,318 million, with YoY growth of 2.2%.
  - India sales were ₹ 20,223 million, YoY growth of 6.4%. The contribution of domestic sales to total sales in Q1FY25 was 67.6% vs. 65.2% in Q1FY24.
  - International sales were ₹ 9,677 million, with YoY de-growth of 4.6%.
- Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were ₹ 6,086 million, resulting in an EBITDA margin of 20.1% vs. 13.1% in Q1FY24. EBITDA increased by 56.4% YoY.
- R&D expenses for the quarter were ₹ 1,257 million, or 4.1% of total revenue from operations, compared to ₹ 1,202 million in Q1FY24 at 4.1% of total revenue from operations.
- Profit before tax (PBT) before exceptional item was ₹ 6,194 million, a growth of 75.5% compared to ₹ 3,529 million in Q1FY24.
- Net Profit (after Minority Interest) was ₹ 5,452 million, YoY growth of 90.1%.
- As per IQVIA (SSA) data, for Q1FY25, the company registered a growth of 8.4% YoY vs. the Indian Pharmaceutical Market (IPM), which grew by 8.7%
- We outperformed the IPM in anti-diabetic, gastrointestinal, neuro/CNS, dermatology, and VMN therapies.
- During the quarter, the Company launched one product in the US and received three approvals from the USFDA, including one tentative approval.
- **Healthy balance sheet** with net cash of ₹38.45 billion as of June 30, 2024.

SSA – Stockist Sales Audit

Key Financial Highlights – Q1FY25 (Consolidated)

All figures in ₹ Mn







Key Financial Highlights – Q1FY25 (Consolidated)

All figures in ₹ Mn

Gross Profit and Gross Margin



EBITDA and EBITDA Margin



PBT (after exceptional item)



PAT (after Minority Interest)



India - Secondary Sales Performance

Mixed performance across all major therapeutic segments in Q1FY25

Acute Therapies



Chronic Therapies



Source: IQVIA SSA data [1] Domestic formulations sales; [2] For three months ended June 30, 2024.

US Business Update

Q1FY25 Sales of ₹ 6,416 million (7.7% YoY de-growth)

- Overall contribution of US sales to total sales was 21.5% in Q1FY25.
- During Q1FY25, the company launched 1 product in the US and received approval for 3 ANDAs from the USFDA, including one tentative approval.
- As of June 30, 2024, the Company had filed 176 ANDAs and two new drug applications (NDAs) with the USFDA. Of these, it had received approvals for 148 ANDAs (including 14 tentative approvals) and 2 NDAs.





Update on USFDA inspections

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Aug-19	EIR Received in Oct 2019
Taloja R&D (India)	Bioequivalence Centre	Oct-22	No observation
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Aug-18	EIR Received in Oct 2018
Note: USFDA conducted a virtual inspection at our manufacturing facilities in Daman from October 5th to 7th, 2020.			

EIR – Establishment Inspection Report indicating successful closure of inspection

Other International Business Update

Q1FY25 Sales of ₹ 3,261 million (2.2% YoY growth)

- Other International Market sales contributed 10.9% to total sales in Q1FY25.
- The Company has a presence mainly in Latin America, Australia and Europe.





Shareholding Pattern as on June 30, 2024



BSE Ticker	539523
NSE Symbol	ALKEM
Shares Outstanding (Mn)	120
MCap (Rs in Mn)*	596,791
Free Float Mcap (Rs in Mn)	260,320
Industry	Pharmaceuticals

***Institution** – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks*

***Non-Institution** – Public, Other Bodies Corporates, Clearing Members, Non-Resident Indians, Hindu Undivided Family and Trusts*

***Share Price** *- Rs 4,991 from NSE as of 28th June, 2024*

Key Financial Highlights – Q1FY25 (Consolidated)

All figures in ₹ Mn

Particulars	Q1FY25	Q1FY24	YoY growth	Q4FY24	QoQ growth
Revenue from Operations	30,318	29,677	2.2%	29,358	3.3%
Gross Profit	19,559	17,692	10.6%	18,284	7.0%
Gross Profit Margin	64.5%	59.6%		62.3%	
EBITDA	6,086	3,892	56.4%	4,020	51.4%
EBITDA Margin	20.1%	13.1%		13.7%	
PBT (before exceptional item)	6,194	3,529	75.5%	3,799	63.0%
Exceptional item	-	-		-125	
PBT (after exceptional item)	6,194	3,529	75.5%	3,673	68.6%
PBT Margin	20.4%	11.9%		12.5%	
PAT (after Minority interest)	5,452	2,867	90.1%	2,936	85.7%
PAT Margin	18.0%	9.7%		10.0%	
EPS (₹ / share)	45.60	23.98	90.1%	24.56	85.7%

Thank You

For any queries, contact:

Purvi Shah
Mobile: +91 84337 00890
E-mail: purvi.shah@alkem.com
Tel: +91 22 3982 9999 Ext: 9447